Drugs / NRT6008
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06278454 | Jan 2024 → Dec 2027 expected | malignant exocrine pancreas neoplasm, metastatic malignant neoplasm in the lymph nodes | Chengdu New Radiomedicine Technology Co. LTD. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRT6008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06278454 ↗ |
| Modality | Other / unclassified | “The efficacy and safety of Yttrium-90 carbon microspheres” NCT06278454 ↗ |
| Route | Other | “NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection” NCT06278454 ↗ |